

**Arvee Laboratories (India) Limited.**

Formerly known as Arvee Laboratories (India) Pvt. Ltd.  
403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,  
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.  
Phone: +91- 2717-430479 | +91- 2717-410819  
e-mail: info@arveelabs.com, Website: www.arveelabs.com  
CIN No. :- L24231GJ2012PLC068778.



Friday, February 13, 2026

To,  
**National Stock Exchange of India Limited**  
**Mumbai**

**Scrip Code: ARVEE**

**ISIN: INE006Z01016**

**Sub: Outcome of Board Meeting held on 13<sup>th</sup> February, 2026**

Dear Sir/Ma'am,

Pursuant to our Board Meeting intimation letter dated 5<sup>th</sup> February, 2026, intimated to the exchange on 5<sup>th</sup> February, 2026 the Board of Directors in their meeting held today on 13<sup>th</sup> February, 2026 have inter-alia amongst others approved the following items:

1. Approve and take on record the unaudited financial results of the Company as per Indian Accounting Standards (INDAS) for the period ended on 31<sup>st</sup> December, 2025.
2. Limited Review Report for the period ended on 31<sup>st</sup> December, 2025

The Board Meeting started at 17:00 Hours and concluded at 18:00 Hours.

Kindly take the above information on record.

Thanking You,

**For, Arvee Laboratories (India) Limited**

**CHAIRMAN CUM MANAGING DIRECTOR**  
**SHALIN SUDHAKARBHAI PATEL**  
**DIN: 01779902**



**Arvee Laboratories (India) Limited.**

Formerly known as Arvee Laboratories (India) Pvt. Ltd.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,  
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.

Phone: +91- 2717-430479 | +91- 2717-410819

e-mail: info@arveelabs.com, Website: www.arveelabs.com

CIN No. :- L24231GJ2012PLC068778.

**ARVEE LABORATORIES (INDIA) LIMITED**

CIN: L24231GJ2012PLC068778

Registered Office: 403, Entice, Nr. Jayantilal Park BRTS,  
Iskcon Bopal Road, Ambli, Ahmedabad - 380058

Tel : +91 – 2717-430479 || +91 – 2717-410819; Website : www.arveelabs.com; Email ID : compliance@arveelabs.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON DECEMBER 31, 2025**

(₹ in Lakhs, except per share data)

Sr. No.	Particulars	Quarter ended			Nine Month Ended		Year ended
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Revenue from Operations	977.95	345.05	890.89	2,071.00	3,203.72	3,848.72
2	Other Income	13.65	22.96	18.71	53.48	44.92	65.73
3	<b>Total Revenue (1+2)</b>	<b>991.60</b>	<b>368.01</b>	<b>909.61</b>	<b>2,124.48</b>	<b>3,248.65</b>	<b>3,914.45</b>
4	<b>Expenses</b>						
	Cost of material consumed	382.85	396.12	629.12	1,327.24	1,632.57	1,887.29
	Changes in inventories of finished goods, work-in-progress and stock in trade	97.50	-383.80	(105.00)	(492.64)	205.15	180.74
	Employee benefit Expenses	111.67	65.55	116.51	344.80	334.56	449.47
	Finance Costs	6.59	4.38	5.34	15.31	17.88	24.87
	Depreciation and amortisation expenses	30.29	30.29	27.51	89.99	88.06	114.88
	Other expenses	223.48	254.44	215.46	682.10	692.71	970.10
	<b>Total Expenses (4)</b>	<b>852.38</b>	<b>366.98</b>	<b>888.93</b>	<b>1,966.80</b>	<b>2,970.93</b>	<b>3,627.36</b>
5	<b>Profit / (Loss) before exceptional items and tax (1-4)</b>	<b>139.22</b>	<b>1.03</b>	<b>20.68</b>	<b>157.68</b>	<b>277.72</b>	<b>287.09</b>
6	Exceptional items	-	-	-	-	-	-
7	<b>Profit / (Loss) before tax (5-6)</b>	<b>139.22</b>	<b>1.03</b>	<b>20.68</b>	<b>157.68</b>	<b>277.72</b>	<b>287.09</b>
8	<b>Tax expense</b>						
	Current Tax	22.62	0.02	5.20	23.15	69.90	58.40
	Deferred Tax	(66.09)	-	-	(66.09)	-	13.96
9	<b>Profit / (Loss) for the period from continuing operations (7-8)</b>	<b>182.69</b>	<b>1.01</b>	<b>15.48</b>	<b>200.61</b>	<b>207.82</b>	<b>214.74</b>
10	Profit / (Loss) from discontinued operations	-	-	-	-	-	-
11	Tax Expense of discontinued operations	-	-	-	-	-	-
12	Profit / (Loss) from discontinued operations (after tax) (10-11)	-	-	-	-	-	-
13	<b>Profit / (Loss) for the period (9+12)</b>	<b>182.69</b>	<b>1.01</b>	<b>15.48</b>	<b>200.61</b>	<b>207.82</b>	<b>214.74</b>
14	Other Comprehensive Income						
	a. Items that will not be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
	b. Items that will be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>182.69</b>	<b>1.01</b>	<b>15.48</b>	<b>200.61</b>	<b>207.82</b>	<b>214.74</b>
	Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	1,102.00	1,102.00	1,102.00	1,102.00	1,102.00	1,102.00
16	<b>Earnings per equity share (for continuing operation)</b>						
	Basic	1.66	0.01	0.14	1.82	1.89	1.95
	Diluted	1.66	0.01	0.14	1.82	1.89	1.95
17	<b>Earnings per equity share (for discontinued operation)</b>						
	Basic	-	-	-	-	-	-
	Diluted	-	-	-	-	-	-
18	<b>Earnings per equity share (for continuing &amp; discontinued operation)</b>						
	Basic	1.66	0.01	0.14	1.82	1.89	1.95
	Diluted	1.66	0.01	0.14	1.82	1.89	1.95
	<b>Paid-up equity share capital (Face value of ₹ 10 each)</b>	<b>1,102.00</b>	<b>1,102.00</b>	<b>1,102.00</b>	<b>1,102.00</b>	<b>1,102.00</b>	<b>1,102.00</b>
	<b>Other Equity excluding Revaluation Reserve</b>	<b>2,333.08</b>	<b>2,042.06</b>	<b>2,017.22</b>	<b>2,333.08</b>	<b>2,017.22</b>	<b>2,024.13</b>



## Arvee Laboratories (India) Limited.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,  
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.  
Phone: +91- 2717-430479 | +91- 2717-410819  
e-mail: info@arveelabs.com, Website: www.arveelabs.com  
CIN No. :- L24231GJ2012PLC068778.



### Notes :

- 1 The aforesaid Financial Results for the quarter and Nine Month ended December 31, 2025 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at its Meeting held on Friday, February 13, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 2 The aforesaid Financial Results for the quarter and Nine Month ended December 31, 2025 have been prepared in accordance with Companies (Indian Accounting Standard) Rule, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 In line with Ind AS - 108 Operating Segments and basis of the review of operations being done by the Senior Management, the operations of the Company fall under the Chemicals business which has been further segmented into Textile and Non Textile segment as reportable segment by the management.
- 4 The Company does not have any subsidiary or Joint venture or associate and hence consolidated results are not applicable.
- 5 The figures for the quarter ended December 31, 2025 are the balancing figures between unaudited figures of the nine months ended December, 31 2025 and unaudited figures in respect of the half year ended September 30, 2025.
- 6 Earnings Per Share is not annualised for the quarter and Nine months ended on the periods mentioned in the above results.
- 7 The figures for the corresponding Previous period have been restated / regrouped wherever necessary, to make them comparable.

For and on behalf of Board of Directors of  
ARVEE LABORATORIES (INDIA) LIMITED

SHALIN SUDHAKARBHAI PATEL  
CHAIRMAN CUM MANAGING DIRECTOR  
DIN: 01779902  
Date: February 13, 2026  
Place: Ahmedabad



**ARVEE LABORATORIES (INDIA) LIMITED**

CIN: L24231GJ2012PLC068778

Registered Office: 403, Entice, Nr. Jayantilal Park BRTS,

Iskcon Bopal Road, Ambli, Ahmedabad - 380058

Tel : +91 – 2717-430479 || +91 – 2717-410819; Website : www.arveelabs.com;

Email ID : compliance@arveelabs.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON DECEMBER 31, 2025**

(₹ in Lakhs)

**Segment wise Revenue, Results & Capital Employed**

Sr. No.	Particulars	Quarter ended	Nine month ended
		31/12/2025	31/12/2025
		Un-Audited	Un-Audited
<b>1</b>	<b>SEGMENT REVENUE</b>		
	A) Textile Segment	109.71	295.57
	B) Non-textile Segment	881.88	1,828.91
	<b>TOTAL</b>	<b>991.60</b>	<b>2,124.48</b>
	<b>Less:</b>		
	Inter Segment Revenue	-	-
	Net Sales/Income From Operations	991.60	2,124.48
<b>2</b>	<b>SEGMENT RESULTS</b>		
	Profit / (Loss) before Tax and Interest from		
	A) Textile Segment	16.05	24.19
	B) Non-textile Segment	126.94	144.95
	<b>TOTAL</b>	<b>142.99</b>	<b>169.14</b>
	<b>Less:</b>		
	i) Interest Expenditure	3.77	11.46
	ii) Other Unallocable Expenditure Net Off	-	-
	Unallocable Income	-	-
	<b>TOTAL PROFIT BEFORE TAX</b>	<b>139.22</b>	<b>157.68</b>
<b>3</b>	<b>CAPITAL EMPLOYED</b>		
	<b>(Segment Assets - Segment Liabilities)</b>		
	A) Textile Segment	1,134.41	1,134.41
	B) Non-textile Segment	2,250.78	2,250.78
	<b>Capital Employed in Segments</b>	<b>3,385.19</b>	<b>3,385.19</b>
	<b>ADD:</b>		
	Unallocable Corporates Assets Less Corporate Liabilities	-	-
	<b>TOTAL</b>	<b>3,385.19</b>	<b>3,385.19</b>



Date: February 13, 2026

Place: Ahmedabad

For and on behalf of Board of Directors of  
ARVEE LABORATORIES (INDIA) LIMITED

*Shalin Sudhakar Bhai Patel*

SHALIN SUDHAKARBHAI PATEL  
CHAIRMAN CUM MANAGING DIRECTOR  
DIN: 01779902



**INDEPENDENT AUDITOR'S REPORT**

To,  
**THE BOARD OF DIRECTORS OF  
ARVEE LABORATORIES (INDIA) LIMITED  
AHMEDABAD**

**Independent Auditors Review Report on Standalone Unaudited Financial Results of the Arvee Laboratories (India) Limited pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015**


1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **ARVEE LABORATORIES (INDIA) LIMITED** ("the Company") for the quarter ended December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Nirav Patel & Associates  
Chartered Accountants  
(Firm's Registration No. 129824W)**

  
CA Nirav Patel  
Partner  
(Membership No. 132409)  
UDIN: 26132409SQQNXF1607



Place: Ahmedabad  
Date: February 13, 2026